Decision: Favourable

Decisions Table

Study Title:

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

  • NREC Code:

    22-NREC-CT-012

  • Decision:

    Favourable

  • Meeting Date:

    26/01/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Mark Doherty

  • PI Institution:

    SVUH

  • Sponsor:

    Inhibrx, Inc / Medspace

Scroll to Top